Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs Novartis AG — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $48.28, while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG pays a 3.02% dividend while iShares MSCI United Kingdom (FTSE) pays none, and iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| EWU | NVS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $48.68 | $168.62 |
52-Week Low | $40.90 | $119.31 |
Market Cap | — | $298.18B |
Enterprise Value | — | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU, the iShares MSCI United Kingdom ETF, trades at $48.64, up 0.7% with strong bullish technical signals from moving averages. The ETF shows mixed institutional activity with recent purchases by Balefire LLC and Fifth Third Bancorp offset by Bank of America trimming its position. UK market sentiment remains influenced by Middle East tensions, oil price volatility, and new political leadership under Prime Minister Andy Burnham.
The ETF's outlook balances UK economic resilience against geopolitical risks. Investment opportunity lies in exposure to FTSE 100 companies amid potential economic stabilization, while risks include ongoing Middle East tensions affecting energy markets and uncertainty around new UK fiscal policies under the Burnham administration.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
